Oryzon Genomics Statistics

Total Valuation

Oryzon Genomics has a market cap or net worth of EUR 252.33 million. The enterprise value is 239.34 million.

Market Cap	252.33M
Enterprise Value	239.34M

Important Dates

The next estimated earnings date is Friday, February 27, 2026.

Earnings Date	Feb 27, 2026
Ex-Dividend Date	n/a

Share Statistics

Oryzon Genomics has 78.85 million shares outstanding. The number of shares has increased by 18.64% in one year.

Current Share Class	78.85M
Shares Outstanding	78.85M
Shares Change (YoY)	+18.64%
Shares Change (QoQ)	-2.99%
Owned by Insiders (%)	15.26%
Owned by Institutions (%)	0.27%
Float	63.41M

Valuation Ratios

PE Ratio	n/a
Forward PE	246.44
PS Ratio	34.29
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-86.84
EV / Sales	32.52
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-6.03

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	n/a
Revenue Per Employee	156,570
Profits Per Employee	-58,639
Employee Count	47
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	-1.91M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +109.70% in the last 52 weeks. The beta is 0.49, so Oryzon Genomics's price volatility has been lower than the market average.

Beta (5Y)	0.49
52-Week Price Change	+109.70%
50-Day Moving Average	3.28
200-Day Moving Average	2.92
Relative Strength Index (RSI)	50.04
Average Volume (20 Days)	724,005

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Oryzon Genomics had revenue of EUR 7.36 million and -2.76 million in losses. Loss per share was -0.04.

Revenue	7.36M
Gross Profit	7.06M
Operating Income	-7.39M
Pretax Income	-4.66M
Net Income	-2.76M
EBITDA	-7.26M
EBIT	-7.39M
Loss Per Share	-0.04

Full Income Statement

Balance Sheet

Cash & Cash Equivalents	n/a
Total Debt	n/a
Net Cash	n/a
Net Cash Per Share	n/a
Equity (Book Value)	n/a
Book Value Per Share	n/a
Working Capital	n/a

Full Balance Sheet

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 95.89%, with operating and profit margins of -100.44% and -37.45%.

Gross Margin	95.89%
Operating Margin	-100.44%
Pretax Margin	-63.35%
Profit Margin	-37.45%
EBITDA Margin	-98.71%
EBIT Margin	-100.44%
FCF Margin	n/a

Dividends & Yields

Oryzon Genomics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-18.64%
Shareholder Yield	-18.64%
Earnings Yield	-1.09%
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a